



S/N 09/117,071

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	KINGSMAN ET AL.	Examiner:	G. LEE
Serial No.:	09/117,071	Group Art Unit:	1632
Filed:	SEPTEMBER 25, 1998	Docket No.:	9192.5USWO
Title:	RETROVIRAL VECTOR AND ITS USE IN GENE THERAPY		

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on September 22, 2000.

By: [Signature]

Name: [Signature]

AMENDMENT & RESPONSE

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed March 28, 2000, Applicants submit the following amendments and remarks.

IN THE SPECIFICATION

Please amend the specification as follows:

At page 1, line 5, please insert ☒ This application claims priority to PCT Application No. WO 97/27310 (filed January 23, 1997) which claims priority to Great Britain Application No. 9601336.2 (filed January 23, 1996) and Great Britain Application No. 9620759 (filed October 4, 1996),--.

IN THE ABSTRACT

Please delete the existing abstract and insert the following in its place:

--The invention provides a method for introducing a heterologous gene into a target cell, wherein a first DNA sequence encoding a replication defective retroviral vector comprising the heterologous gene and second DNA sequences encoding *env* and *gag-pol* are used to convert a subject's cell into a producer cell. The producer cell is capable of producing replicating defective